Bellerophon Appoints Naseem Amin, M.D. as Chairman of its Board of Directors
May 26, 2021 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing...
Bellerophon Provides Clinical Program Update and Reports First Quarter 2021 Financial Results
May 11, 2021 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing...
Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2020 Financial Results
March 11, 2021 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing...
Bellerophon to Present at the H.C. Wainwright Global Life Sciences Conference
March 02, 2021 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing...
Bellerophon to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
January 04, 2021 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing...
Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treatment of Fibrotic Interstitial Lung Disease
December 01, 2020 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing...
Bellerophon Therapeutics Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse® for the Treatment of COVID-19
November 23, 2020 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing...
Bellerophon to Present at the H.C. Wainwright 6th Annual Israel Conference
November 11, 2020 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing...
Bellerophon Provides Clinical Program Update and Reports Third Quarter 2020 Financial Results
November 05, 2020 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing...
Bellerophon to Present Results from its Phase 2 iNO-PF Study of INOpulse® for the Treatment of Fibrotic Interstitial Lung Disease at Upcoming Scientific Conferences
October 29, 2020 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing...